Last week's judicial decision at last in Bilski v. Kappos didn't have much fallout for Myriad Genetics Inc., which is preoccupied anyway with its appeal of the more surprising March ruling that involves patent claims related to the BRCA1 and BRCA2 genes. (BioWorld Insight) Read More
